Accession Number : ADA320291
Title : Radioimmunotherapy of Metastatic Breast Cancer Using Radiolabeled Tumor Specific Antibodies.
Descriptive Note : Annual rept. 1 Sep 95-31 Aug 96,
Corporate Author : NEW YORK UNIV MEDICAL CENTER NY
Personal Author(s) : Wasserheit, Carolyn
PDF Url : ADA320291
Report Date : SEP 1996
Pagination or Media Count : 20
Abstract : Over the last year, we have opened a clinical trial using In-111 MX-DTPA huBrE-3 in patients with metastatic breast cancer. Three patients have been studied with no significant toxicity. Data available on two of the patients reveal that 22 of 26 known sites of metastasis were identified by scans and two previously unknown sites were identified. Plasma T1/2 clearance averaged 45.7 + or - 28.1 hours. Whole body doses extrapolated to Y-90 huBrE-3 averaged 2.55 + or - 0.39 rads/mCi with tumor doses 95.5 + or - 8.3 rads/mCi. The degree of immunogenicity on repeated serum sampling was negligible. The results obtained support the further evaluation of Y-90 huBrE-3 as a potential therapeutic agent. In the laboratory, experiments have been conducted in the nude mouse, human tumor xenograft model. A synergistic anti-tumor effect was observed in mice treated with a combination of topotecan and 90-Y MX-DTPA BrE-3 with complete eradication of tumor in the treated mice. We plan to continue these preclinical studies and hope to conduct a clinical trial using combination radioimmunoconjugate and topotecan in patients with advanced breast cancer.
Descriptors : *ANTIBODIES, *METASTASIS, *RADIOIMMUNITY, *BREAST CANCER, TOXICITY, CLINICAL MEDICINE, NEOPLASMS, SAMPLING, DOSAGE, THERAPY, PATIENTS, MICE, BLOOD SERUM, LABELED SUBSTANCES, RADIOACTIVE ISOTOPES, IMMUNOGENS.
Subject Categories : Biochemistry
Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE